Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer

NCT03975231 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03975231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03975231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
September 14, 2020
Completion date
October 5, 2027
Enrollment
6 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

braf np_004324.2:p.v600e, braf v600k mutation present, thyroid gland anaplastic carcinoma